边缘供肝的评估和应用
|
摘要
<正>肝移植是治疗终末期肝病的唯一有效手段。目前,供肝短缺是制约临床肝移植发展的瓶颈,大量病人在等待肝移植过程中死亡。另一方面,为了缓解供体器官的短缺,边缘供肝,也称作扩大标准供肝逐渐应用于临床肝移植。特别是在中国实施公民逝世后器官捐献(DCD)来源器官的背景条件下,供体由于在ICU抢救等过程中出现低血压、缺血、缺氧,以及大量血管活性药物的应用,DCD来源供体出现"边缘供肝"的情况
引文
[1]Vodkin I,Kuo A.Extended Criteria Donors in Liver Transplantation[J].Clin Liver Dis,2017,21(2):289-301.
[2]Nemes B,Gámán G,Polak WG,et al.Extended-criteria donors in liver transplantation Part II:reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation[J].Expert Rev Gastroenterol Hepatol,2016,10(7):841-859.
[3]Pezzati D,Ghinolfi D,De Simone P,et al.Strategies to optimize the use of marginal donors in liver transplantation[J].World J Hepatol,2015,7(26):2636-2647.
[4]Routh D,Sharma S,Naidu CS,et al.Comparison of outcomes in ideal donor and extended criteria donor in deceased donor liver transplant:a prospective study[J].Int J Surg,2014,12(8):774-777.
[5]Sotiropoulos GC,Tagkalos E,Fouzas I,et al.Liver transplantation for hepatocellular carcinoma using extended criteria donor grafts[J].Transplant Proc,2012,44(9):2730-2733.
[6]Sass DA,Reich DJ.Liver transplantation in the 21st century:expanding the donor options[J].Gastroenterol Clin North Am,2011,40(3):641-645.
[7]Brice1o J,Ciria R,de la Mata M,et al.Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease scoreera[J].Transplantation,2010,90(5):530-539.
[8]Naranjo-Izurieta JR,Ruiz de Azúa-López Z,Lameirao J,et al.Orthotopic Liver Transplantation:Preliminary Analysis of Complications With Grafts From Elderly Donors[J].Transplant Proc,2018,50(2):644-645.
[9]Roullet S,Defaye M,Quinart A,et al.Liver Transplantation With Old Grafts:A Ten-Year Experience[J].Transplant Proc,2017,49(9):2135-2214.
[10]Detry O.Donor Age in Liver Transplantation:Donation after Circulatory Death[J].J Am Coll Surg,2015,221(3):779.
[11]Detry O,Deroover A,Meurisse N,et al.Donor age as a risk factor in donation after circulatory death liver transplantation in a controlled withdrawal protocol programme[J].Br J Surg,2014,101(7):784-792.
[12]陈栋,魏来,蒋继贫,等.老年公民逝世后器官捐献肝移植的临床疗效[J].中华消化外科杂志,2016,15(5):466-470.
[13]Kulik U,Lehner F,Klempnauer J,et al.Primary non-function is frequently associated with fatty liver allografts and high mortality after retransplantation[J].Liver Int,2017,37(8):1219-1228.
[14]Wu C,Lu C,Xu C.Short-term and long-term outcomes of liver transplantation using moderately and severely steatoticdonor livers:A systematic review[J].Medicine(Baltimore),2018,97(35):e12026.
[15]Hamar M,Selzner M.Steatotic donor livers:Where is the risk-benefit maximized[J]?Liver Transpl,2017,23(S1):S34-S39.
[16]郑树森.中国心脏死亡捐献器官评估与应用专家共识[J].中华移植杂志(电子版)2014,8(3):117-122.
[17]Wei L,Chen D,Zhang B,et al.Long-term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen-positive donors in a Chinese population[J].J Viral Hepat,2018,25(12):1576-1581.
[18]Lee WC,Chou HS,Lee CS,et al.Viral activity and outcome of hepatitis B surface antigen-positive grafts in deceased liver transplantation[J].JViral Hepat,2018,25(7):874-877.
[19]Ballarin R,Cucchetti A,Russo FP.Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positivedonors[J].World J Gastroenterol,2017,23(12):2095-2105.
[20]Loggi E,Conti F,Cucchetti A,et al.Liver grafts from hepatitis B surface antigen-positive donors:A review of the literature[J].World J Gastroenterol,2016,22(35):8010-8016.
[21]Mitchell RA,Hussaini T,Yau AH,et al.Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission,Transplant[J].Direct,2018,4(3):e347.
[22]美国移植协会《实体器官移植感染疾病诊疗指南》2013年第3版介绍(续一)[J].实用器官移植电子杂志,2014,2(4):196-205.
[23]美国移植协会《实体器官移植感染疾病诊疗指南》2013年第3版介绍(续二)实体器官移植中供体来源的感染[J].实用器官移植电子杂志,2014,2(5):266-270.
[24]林俊.原发性中枢神经系统恶性肿瘤供者在器官移植中的应用[J].临床外科杂志,2016,24(10):737-740.
[2]Nemes B,Gámán G,Polak WG,et al.Extended-criteria donors in liver transplantation Part II:reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation[J].Expert Rev Gastroenterol Hepatol,2016,10(7):841-859.
[3]Pezzati D,Ghinolfi D,De Simone P,et al.Strategies to optimize the use of marginal donors in liver transplantation[J].World J Hepatol,2015,7(26):2636-2647.
[4]Routh D,Sharma S,Naidu CS,et al.Comparison of outcomes in ideal donor and extended criteria donor in deceased donor liver transplant:a prospective study[J].Int J Surg,2014,12(8):774-777.
[5]Sotiropoulos GC,Tagkalos E,Fouzas I,et al.Liver transplantation for hepatocellular carcinoma using extended criteria donor grafts[J].Transplant Proc,2012,44(9):2730-2733.
[6]Sass DA,Reich DJ.Liver transplantation in the 21st century:expanding the donor options[J].Gastroenterol Clin North Am,2011,40(3):641-645.
[7]Brice1o J,Ciria R,de la Mata M,et al.Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease scoreera[J].Transplantation,2010,90(5):530-539.
[8]Naranjo-Izurieta JR,Ruiz de Azúa-López Z,Lameirao J,et al.Orthotopic Liver Transplantation:Preliminary Analysis of Complications With Grafts From Elderly Donors[J].Transplant Proc,2018,50(2):644-645.
[9]Roullet S,Defaye M,Quinart A,et al.Liver Transplantation With Old Grafts:A Ten-Year Experience[J].Transplant Proc,2017,49(9):2135-2214.
[10]Detry O.Donor Age in Liver Transplantation:Donation after Circulatory Death[J].J Am Coll Surg,2015,221(3):779.
[11]Detry O,Deroover A,Meurisse N,et al.Donor age as a risk factor in donation after circulatory death liver transplantation in a controlled withdrawal protocol programme[J].Br J Surg,2014,101(7):784-792.
[12]陈栋,魏来,蒋继贫,等.老年公民逝世后器官捐献肝移植的临床疗效[J].中华消化外科杂志,2016,15(5):466-470.
[13]Kulik U,Lehner F,Klempnauer J,et al.Primary non-function is frequently associated with fatty liver allografts and high mortality after retransplantation[J].Liver Int,2017,37(8):1219-1228.
[14]Wu C,Lu C,Xu C.Short-term and long-term outcomes of liver transplantation using moderately and severely steatoticdonor livers:A systematic review[J].Medicine(Baltimore),2018,97(35):e12026.
[15]Hamar M,Selzner M.Steatotic donor livers:Where is the risk-benefit maximized[J]?Liver Transpl,2017,23(S1):S34-S39.
[16]郑树森.中国心脏死亡捐献器官评估与应用专家共识[J].中华移植杂志(电子版)2014,8(3):117-122.
[17]Wei L,Chen D,Zhang B,et al.Long-term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen-positive donors in a Chinese population[J].J Viral Hepat,2018,25(12):1576-1581.
[18]Lee WC,Chou HS,Lee CS,et al.Viral activity and outcome of hepatitis B surface antigen-positive grafts in deceased liver transplantation[J].JViral Hepat,2018,25(7):874-877.
[19]Ballarin R,Cucchetti A,Russo FP.Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positivedonors[J].World J Gastroenterol,2017,23(12):2095-2105.
[20]Loggi E,Conti F,Cucchetti A,et al.Liver grafts from hepatitis B surface antigen-positive donors:A review of the literature[J].World J Gastroenterol,2016,22(35):8010-8016.
[21]Mitchell RA,Hussaini T,Yau AH,et al.Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission,Transplant[J].Direct,2018,4(3):e347.
[22]美国移植协会《实体器官移植感染疾病诊疗指南》2013年第3版介绍(续一)[J].实用器官移植电子杂志,2014,2(4):196-205.
[23]美国移植协会《实体器官移植感染疾病诊疗指南》2013年第3版介绍(续二)实体器官移植中供体来源的感染[J].实用器官移植电子杂志,2014,2(5):266-270.
[24]林俊.原发性中枢神经系统恶性肿瘤供者在器官移植中的应用[J].临床外科杂志,2016,24(10):737-740.